Cancer Stem-Like Cells Evade CD8+CD103+ Tumor-Resident Memory T (TRM) Lymphocytes by Initiating an Epithelial-to-Mesenchymal Transition Program in a Human Lung Tumor Mode

Researchers supported the rational design of immunotherapeutic strategies targeting cancer stem cells to optimize their responsiveness to local CD8+CD103+ TRM cells for more efficient anticancer treatments.